ATXI Stock Price, Avenue Therapeutics Inc Quote, Chart

Market Summary

USD3.86+0.23

Delayedas of 17 May 2024, 01:09 pm

6.34%

ATXI Stock Price

View Fullscreen

ATXI RSI Chart

ATXI Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.47

Price/Free Cashflow

-0.31

ATXI Price/Sales (Trailing)

ATXI Profitability

Return on Equity

-381.19%

Return on Assets

-218.58%

Free Cashflow Yield

-321.98%

ATXI Fundamentals

ATXI Earnings

Earnings (TTM)

-7.2M

Earnings Growth (Yr)

42.79%

Earnings Growth (Qtr)

-804.86%

Breaking Down ATXI Revenue

52 Week Range

3.98

(Low)(High)

Last 7 days

-12.5%

Last 30 days

-63.3%

Last 90 days

-66.8%

Trailing 12 Months

-95.5%

How does ATXI drawdown profile look like?

ATXI Financial Health

ATXI Investor Care

Shares Dilution (1Y)

791.03%

Diluted EPS (TTM)

-220.5

Tracking the Latest Insider Buys and Sells of Avenue Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 16, 2024	fortress biotech, inc.	acquired	-	-	413,507	-
Jan 02, 2024	fortress biotech, inc.	acquired	-	-	2,101,500	-
Dec 11, 2023	davidow robert l	sold	-36,960	0.14	-264,000	-
Dec 11, 2023	davidow robert l	sold	-2,800	0.14	-20,000	-
Dec 11, 2023	davidow robert l	sold	-2,700	0.15	-18,000	-
Dec 11, 2023	davidow robert l	sold	-17,640	0.14	-126,000	-
Dec 11, 2023	davidow robert l	sold	-17,920	0.14	-128,000	-
Dec 11, 2023	davidow robert l	sold	-8,540	0.14	-61,000	-
Sep 08, 2023	rosenwald lindsay a md	bought	251,046	0.72	348,675	-
Sep 08, 2023	fortress biotech, inc.	bought	301,255	0.72	418,410	-

Which funds bought or sold ATXI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-459	4,512	-%
May 15, 2024	Cubist Systematic Strategies, LLC	sold off	-100	-1,756	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	new	-	98,962,000	98,962,000	0.06%
May 15, 2024	Tower Research Capital LLC (TRC)	added	30.2	216	1,313	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	547	21,831	26,259	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-63.29	-3,099	1,549	-%
May 15, 2024	Royal Bank of Canada	added	7.78	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-14,405	-	-%
May 13, 2024	HRT FINANCIAL LP	added	82.84	2,000	6,000	-%
May 13, 2024	UBS Group AG	sold off	-100	-174	-	-%

Are Funds Buying or Selling ATXI?

Are funds buying ATXI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATXI

No. of Funds

Unveiling Avenue Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 02, 2024	davidow robert l	2.9%	17,206	SC 13G/A
Apr 17, 2024	fortress biotech, inc.	8.0%	3,564,059	SC 13D/A
Jan 02, 2024	sabby management, llc	4.99%	661,056	SC 13G/A
Dec 13, 2023	davidow robert l	9.89%	1,309,800	SC 13G/A
Nov 28, 2023	davidow robert l	14.5%	1,926,800	SC 13G
Sep 18, 2023	fortress biotech, inc.	12.1%	1,049,056	SC 13D/A
Feb 14, 2023	cvi investments, inc.	4.9%	251,011	SC 13G/A
Jan 06, 2023	fortress biotech, inc.	11.3%	578,227	SC 13D/A
Jan 04, 2023	sabby management, llc	5.53%	264,000	SC 13G
Dec 14, 2022	nantahala capital management, llc	0.0%	0	SC 13G/A

Recent SEC filings of Avenue Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 13, 2024	8-K	Current Report
May 10, 2024	EFFECT	EFFECT
May 10, 2024	424B3	Prospectus Filed
May 10, 2024	424B5	Prospectus Filed
May 06, 2024	DEF 14A	DEF 14A
May 06, 2024	DEFA14A	DEFA14A
May 06, 2024	S-3	S-3
May 02, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Avenue Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Avenue Therapeutics Inc News

Latest updates

Avenue Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	78.9%	3,310	1,850	502	1,666	8,447	6,845	575	1,005	1,956	3,960	688	1,191	1,944	3,245	4,352	5,331	6,696	8,915	13,878	15,677	29,763
Cash Equivalents	79.1%	3,194	1,783	161	1,571	8,236	6,708	217	890	1,833	3,763	585	1,121	1,825	3,132	4,325	5,257	6,574	8,745	8,741	10,455	29,448
Liabilities	18.1%	1,412	1,196	5,024	7,812	10,604	3,579	614	407	797	509	848	549	469	886	1,118	1,230	923	2,115	1,917	1,773	9,412
Current Liabilities	18.1%	1,412	1,196	5,024	7,812	10,604	3,579	614	407	797	509	848	549	469	886	1,118	1,230	923	2,115	1,917	1,773	9,412
Shareholder's Equity	20.0%	1,898	1,582	-	-	-2,157	3,905	-	598	1,159	3,451	-	642	1,475	2,359	3,234	4,101	5,773	6,800	11,961	13,904	20,351
Retained Earnings	-4.8%	-95,300	-90,928	-91,568	-92,094	-88,087	-80,551	-81,100	-80,500	-79,860	-76,999	-76,086	-75,200	-74,266	-73,268	-72,275	-71,247	-69,359	-68,117	-62,702	-60,460	-53,478
Additional Paid-In Capital	6.1%	98,104	92,507	87,917	86,757	86,634	84,456	81,087	81,060	81,017	80,450	75,924	75,855	75,739	75,625	75,507	75,346	75,130	74,915	74,661	74,362	73,827
Shares Outstanding	72.9%	590	341	120	106	91.00	64.00	19.00	20.00	19.00	19.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-
Minority Interest	-1.1%	-938	-928	-872	-810	-705	-639	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	8,522	-	-	-	2,946	-	-	-	16,813	-	-	-	72,343	-	-	-	40,871	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-34.3%	-3,120	-2,324	-889	-4,665	-1,573	-4,169	-554	-943	-1,930	-1,203	-536	-704	-1,307	-1,193	-932	-1,317	-1,171	-4,996	-1,714	-13,981	-5,568
Share Based Compensation	-37.8%	191	307	561	27.00	11.00	12.00	25.00	43.00	569	143	69.00	116	114	118	161	216	215	254	299	535	751
Cashflow From Investing	-	-	-	-1,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,000	5,000	-	-5,000	-
Cashflow From Financing	14.8%	4,531	3,946	479	-	3,101	10,660	-119	-	-	-	-	-	-	-	-	-	-	-	-	-12.00	32,345

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATXI Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 2,392	$ 1,215
Research and development – licenses acquired	0	4,230
General and administrative	1,316	984
Loss from operations	(3,708)	(6,429)
Other income (expense):
Interest income	49	37
Financing costs – warrant liabilities	0	(332)
Loss on settlement of common stock warrant liabilities	(574)	0
Change in fair value of warrant liabilities	(116)	(878)
Total other income (expense)	(641)	(1,173)
Net loss	(4,349)	(7,602)
Net loss attributable to non-controlling interests	(9)	(66)
Net loss attributable to common stockholders	$ (4,340)	$ (7,536)
Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share)	$ (15.4)	$ (101.57)
Weighted average number of common shares outstanding, basic and diluted (in shares)	562,031	74,198

ATXI Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,194	$ 1,783
Prepaid expenses and other current assets	116	67
Total assets	3,310	1,850
Current Liabilities:
Warrant liability	413	586
Total current liabilities	1,412	1,196
Total liabilities	1,412	1,196
Commitments and contingencies
Stockholders’ equity (deficit)
Preferred stock ($0.0001 par value), 2,000,000 shares authorized Class A Preferred stock, 250,000 shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Common shares, 590,188 and 341,324 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	3
Additional paid-in capital	98,104	92,507
Accumulated deficit	(95,268)	(90,928)
Total stockholders’ equity attributed to the Company	2,836	1,582
Non-controlling interests	(938)	(928)
Total stockholders’ equity	1,898	654
Total liabilities and stockholders’ equity	3,310	1,850
Nonrelated Party [Member]
Current Liabilities:
Accounts payable and accrued expenses	647	287
Related Party [Member]
Current Liabilities:
Accounts payable and accrued expenses	$ 352	$ 323

About Avenue Therapeutics Inc

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.

CEO	Dr. Alexandra MacLean M.D.
WEBSITE	avenuetx.com
INDUSTRY	Biotechnology
EMPLOYEES	2

Avenue Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Avenue Therapeutics Inc? What does ATXI stand for in stocks?

ATXI is the stock ticker symbol of Avenue Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avenue Therapeutics Inc (ATXI)?

As of Thu May 16 2024, market cap of Avenue Therapeutics Inc is 3.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATXI stock?

You can check ATXI's fair value in chart for subscribers.

What is the fair value of ATXI stock?

You can check ATXI's fair value in chart for subscribers. The fair value of Avenue Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avenue Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATXI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avenue Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ATXI is over valued or under valued. Whether Avenue Therapeutics Inc is cheap or expensive depends on the assumptions which impact Avenue Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATXI.